Ultragenyx Pharmaceutical Inc (RARE)

57.19
2.97 5.48
NASDAQ : Health Care
Prev Close 54.22
Open 53.95
Day Low/High 53.65 / 58.17
52 Wk Low/High 46.52 / 135.43
Volume 928.91K
Avg Volume 699.30K
Exchange NASDAQ
Shares Outstanding 39.02M
Market Cap 2.10B
EPS -4.00
P/E Ratio 16.58
Div & Yield N.A. (N.A)

Latest News

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

Ultragenyx Announces Data Presentations Of RhGUS And RhPPCA At 12th Annual WORLD Symposium™

Ultragenyx Announces Data Presentations Of RhGUS And RhPPCA At 12th Annual WORLD Symposium™

Ultragenyx CEO Emil Kakkis, M.D. Ph.D., Receives 2016 Lysosomal Disease Network Award for Innovation and Achievement

Ultragenyx Pharmaceutical (RARE) Stock Gets 'Outperform' Rating at Leerink

Ultragenyx Pharmaceutical (RARE) Stock Gets 'Outperform' Rating at Leerink

Leerink began coverage of Ultragenyx Pharmaceutical (RARE) stock with an 'outperform' rating and $80 price target on Friday morning.

Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia

Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia

Substantial Reduction in Bone Disease Demonstrated With Two Different Instruments

Ultragenyx Announces Update To UX007 Development Program In Glucose Transporter Type-1 Deficiency Syndrome

Ultragenyx Announces Update To UX007 Development Program In Glucose Transporter Type-1 Deficiency Syndrome

Pivotal Phase 3 Movement Disorder Study to Initiate Mid-2016